Latest Breaking News On - Radioligand therapy - Page 4 : comparemela.com

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

Preclinical studies show uTREAT® effective in treating non-small cell lung cancer Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis.

Ulrich krasilnikoffCurasightas curasightPositron emissions tomographyRadioligand therapyTheranostic platform

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and commence.

United statesSamir shahIsabella zinckParag mahantiRichard jarvisJulie masowSatoshi sugimotoMarlena abdinoorNovartis adrsNicole zinsli sommMichael meoSandoz adrsSloan simpsonExchange commissionSwiss exchangeAmerican depositary receipts

Novartis executes Sandoz Spin-off; To fully focus on innovative medicines

Novartis executes Sandoz Spin-off; To fully focus on innovative medicines
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Novartis adrsSandoz adrsSwiss exchangeAmerican depositary receiptsVas narasimhanGene therapyRadioligand therapyOperating incomeSandoz spin off

Lilly enters radiopharma space with $1 4B buyout of Point Biopharma

Indianapolis-based Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma company a pipeline of preclinical and clinical radioligand therapies for cancer. The purchase price is an 87% premium to Point’s closing stock price on Oct. 2, and a 68% premium to the 30-day volume-weighted average price. Shares (NASDAQ:PNT) of Point, also of Indianapolis, rose 84.9%, or $5.67, to close at $12.36 on Oct. 3.

Eli lillyPoint biopharma global incIndianapolis based eli lillyPoint biopharma globalEli lilly and coPoint biopharma global incRadioligand therapyPnt 2002M amp aRadiopharma therapiesPnt 2003

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyBaja californiaMarlena abdinoorJeff legosParag mahantiRichard jarvisSatoshi sugimotoIsabella zinckSamir shahSloan simpsonJulie masowNicole zinsli sommMichael meoGlobal head of oncology development at novartisExchange commission